Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

2.2K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
2.2K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

1.2K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.2K
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

279
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
279
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

2.0K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
2.0K
Prevention of Further Absorption of Poison01:14

Prevention of Further Absorption of Poison

1.4K
In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
1.4K
Diphtheria01:28

Diphtheria

175
Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
175

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimal approach to standardized documentation in epilepsy clinics: A scoping review.

Epilepsia·2026
Same author

Screening and Management of Depression and Anxiety in People With Epilepsy: A Quality Improvement Study.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2025
Same author

Delineating the pathogenic threshold and phenotypic spectrum of SCA27B: findings from a large French-Canadian cohort.

Journal of neurology·2025
Same author

Reduction of generalized tonic-clonic seizures following vagus nerve stimulation therapy: CORE-VNS Study 24-month follow-up.

Epilepsia·2025
Same author

New-onset Vascular Events in Older People with Epilepsy Over Six Years: A Cohort Study of the Canadian Longitudinal Study on Aging (CLSA) (S19.010).

Neurology·2025
Same author

Preeclampsia and the Long-Term Risk of Developing Neurological Disorders Requiring Hospital Admission.

Neuroepidemiology·2024

Related Experiment Video

Updated: May 2, 2026

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

15.6K

Medical treatment for botulism.

Colin H Chalk1, Tim J Benstead, Mark Keezer

  • 1Departments of Medicine and Neurology & Neurosurgery, McGill University, Montreal General Hospital - Room L7-313, 1650 Cedar Avenue, Montreal, Quebec, Canada, H3G 1A4.

The Cochrane Database of Systematic Reviews
|February 22, 2014
PubMed
Summary

Human-derived botulinum immune globulin (BIG) significantly reduces hospitalization, mechanical ventilation, and feeding durations for infant botulism. This treatment shows promise for improving outcomes in this rare paralytic illness.

More Related Videos

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
10:30

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

Published on: December 27, 2013

5.0K
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
07:05

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

24.5K

Related Experiment Videos

Last Updated: May 2, 2026

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

15.6K
A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
10:30

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

Published on: December 27, 2013

5.0K
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
07:05

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

24.5K

Area of Science:

  • Neurology
  • Infectious Diseases
  • Pharmacology

Background:

  • Botulism is a severe paralytic illness caused by Clostridium botulinum neurotoxins.
  • Current management relies heavily on supportive care, with limited evidence for other medical interventions.
  • This review is an update of previous findings on botulism treatments.

Purpose of the Study:

  • To evaluate the efficacy of medical treatments for botulism.
  • To assess impacts on mortality, hospitalization duration, mechanical ventilation, nutritional support, and adverse events.
  • To update the evidence base for botulism therapeutic strategies.

Main Methods:

  • Searched multiple databases (Cochrane, CENTRAL, MEDLINE, EMBASE) up to March 2013.
  • Included randomized and quasi-randomized controlled trials of botulism treatments.
  • Focused on human-derived botulinum immune globulin (BIG), equine antitoxin, plasma exchange, 3,4-diaminopyridine, and guanidine.

Main Results:

  • One trial involving 59 participants treated with BIG met inclusion criteria.
  • BIG significantly reduced hospitalization (3.1 weeks shorter), mechanical ventilation (2.6 weeks shorter), and feeding durations (6.4 weeks shorter).
  • No significant difference in adverse events was observed; mortality data was insufficient for analysis.

Conclusions:

  • Human-derived botulinum immune globulin (BIG) is supported by evidence for treating infant intestinal botulism.
  • BIG demonstrated significant benefits in reducing key recovery metrics in a single RCT.
  • No evidence was found for other medical treatments like equine antitoxin.